Oncology Corporate Profile
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.
|Actiq??||fentanyl citrate||ACTIQ is an opioid analgesic indicated only for management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.|
|Bendeka_?||bendamustine hydrochloride||Bendamustine hydrochloride is an alkylating drug indicated for treatment of patients with:|
_??Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
_??Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
|Fentora??||fentanyl buccal||FENTORA is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who|
are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant
are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg of
transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic
dose of another opioid daily for a week or longer.
This product must not be used in opioid non-tolerant patients because life-threatening hypoventilation and death could occur
at any dose in patients not on a chronic regimen of opioids. For this reason, FENTORA is contraindicated in the management of
acute or postoperative pain.
FENTORA is intended to be used only in the care of opioid tolerant cancer patients and only by healthcare professionals who
are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.
|Synribo_?||omacetaxine mepesuccinate||SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO.|
|Tevagrastim??||tbo_?_filgrastim||Tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile|
neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.
Tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPC).
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an
absolute neutrophil count (ANC) of ? 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of Tevagrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Tevagrastim is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x
109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
|Treanda??||bendamustine hydrochloride||Chronic Lymphocytic Leukemia (CLL)|
TREANDA for Injection is an alkylating drug indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
Non-Hodgkin_?_s Lymphoma (NHL)
TREANDA for Injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin_?_s lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
|Trisenox??||arsenic trioxide||TRISENOX is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the translocation or PML/RAR-alpha gene expression.|
|Brand / Product||Class||Area of Study||Phase||Partnership|
|custirsen / TV-1011 (OGX-011)||clusterin inhibitor||1st line metastatic castrate-resistant Prostate cancer (CRPC)||III||Oncogenex|
|custirsen / TV-1011 (OGX-011)||clusterin inhibitor||1st line metastatic Non Small Cell Lung Cancer (NSCLC)||III||Oncogenex|
|custirsen (+ cabazitaxel) / TV-1011 (OGX-011)||clusterin inhibitor||2nd line metastatic castrate-resistant prostate cancer (CRPC)||III||Oncogenex|
|Rituxan_ / rituximab||anti-CD20 monoclonal antibody||Non-Hodgkin's Lymphoma (NHL)||III|
|Treanda_ / bendamustine||alkylating agent||1st line metastatic Non-Hodgkin's Lymphoma (NHL)||III|
|Trisenox_ / arsenic trioxide||taxane (a synthetic retinoid)||Acute Myelogenous Leukemia (AML)||III|
|lestaurtinib / CEP-701||Flt-3 kinase inhibitor||Acute Myelogenous Leukemia (AML)||II|
|tamibarotene (+ arsenic trioxide) / INNO-507||RAR alpha/beta agonist||Acute Promyelocytic Leukemia (APL)||II||CytRx|
|CEP-32496||BRAF kinase inhibitor||Breast cancer||II|
|obatoclax / CEP-41601||pan-inhibitor of Bcl-2 proteins||Follicular Non-Hodgkin's Lymphoma (f-NHL)||II|
|obatoclax / CEP-41601||pan-inhibitor of Bcl-2 proteins||Hodgkin's Lymphoma||II|
|obatoclax / CEP-41601||pan-inhibitor of Bcl-2 proteins||Myelodysplastic Syndrome (MDS)||II|
|obatoclax / CEP-41601||pan-inhibitor of Bcl-2 proteins||Myelofibrosis||II|
|lestaurtinib / CEP-701||Flt-3 kinase inhibitor||Myeloproliferative disorders||II|
|tamibarotene / INNO-507||RAR alpha/beta agonist||Non Small Cell Lung Cancer (NSCLC)||II||CytRx|
|CEP-9722||PARP inhibitor||Non Small Cell Lung Cancer (NSCLC)||II|
|CT-011||PD-1 inhibitor||Various cancer types||II||Curetech Ltd.|
|Quinamed_ / amonafide dihydrochloride||topoisomerase II inhibitor||Breast cancer||II|
|Quinamed_ / amonafide dihydrochloride||topoisomerase II inhibitor||Ovarian cancer||II|
|Quinamed_ / amonafide dihydrochloride||topoisomerase II inhibitor||Prostate cancer||II|
|Synribo_ / omacetaxine mepesuccinate||protein synthesis inhibitor||Acute Myelogenous Leukemia (AML)||II|
|Synribo_ / omacetaxine mepesuccinate||protein synthesis inhibitor||Myelodysplastic Syndrome (MDS)||II|
|Treanda_ (+ Rituxan_) / bendamustine||alkylating agent||Mantle Cell Lymphoma (MCL)||II|
|obatoclax / CEP-41601||pan-inhibitor of Bcl-2 proteins||1st line metastatic Small Cell Lung Cancer (SCLC)||I|
|obatoclax / CEP-41601||pan-inhibitor of Bcl-2 proteins||Acute Myelogenous Leukemia (AML)||I|
|obatoclax / CEP-41601||pan-inhibitor of Bcl-2 proteins||Mantle Cell Lymphoma (MCL)||I|
|CEP-18770||proteasome inhibitor||Multiple Myeloma||I|
|obatoclax / CEP-41601||pan-inhibitor of Bcl-2 proteins||Myelodysplastic Syndrome (MDS)||I|
|CEP-11981||VEGF-R/Tie-2 kinase inhibitor||Various cancer types||I|
|CEP-37440||ALK/FAK kinase inhibitor||Various cancer types||I|
|CEP-9722||PARP inhibitor||Various cancer types||I|
|Treanda_ (+ Velcade_) / bendamustine||alkylating agent||Multiple Myeloma||I|
|CXS-299||cell cycle inhibitor||Various cancer types||Preclinical|
|CEP-32496||B-RAF kinase inhibitor||Various cancer types||Preclinical||Champions Biotechnology|
View additional information on product candidates here »
3/27/2017 11:00 pm
3/27/2017 12:03 pm
3/24/2017 02:05 pm
3/23/2017 02:01 pm
3/23/2017 01:00 pm
3/23/2017 10:05 am
3/23/2017 08:03 am
3/23/2017 08:02 am
3/23/2017 08:01 am
3/23/2017 07:03 am
3/23/2017 07:03 am
3/21/2017 02:05 pm
3/21/2017 12:01 am
3/20/2017 02:03 pm
3/17/2017 01:05 pm
3/16/2017 05:05 pm
[Business Wire] - Teva Pharmaceutical Industries Ltd. today announced the launch of the Authorized Generic of Minastrin® 24 Fe1 1 mg/20 mcg in the U.S.
3/16/2017 05:05 pm
3/14/2017 11:00 am
3/13/2017 03:01 pm
3/13/2017 03:00 pm
[Business Wire] - Teva Pharmaceutical Industries Ltd. will host a live audio webcast at the Barclays Global Healthcare Conference in Miami, Florida.
3/9/2017 05:00 pm
3/8/2017 06:05 pm
3/8/2017 12:05 pm
3/7/2017 09:02 pm
3/6/2017 05:04 pm